CapsoVision (CV) Competitors

CapsoVision logo
$6.31 -0.51 (-7.48%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$6.33 +0.02 (+0.32%)
As of 11/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CV vs. STAA, TNDM, AORT, ATEC, and DRTS

Should you buy CapsoVision stock or one of its competitors? CapsoVision's main competitors and comparable companies include STAAR Surgical (STAA), Tandem Diabetes Care (TNDM), Artivion (AORT), Alphatec (ATEC), and Alpha Tau Medical (DRTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does CapsoVision compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

96.7% of STAAR Surgical shares are owned by institutional investors. 39.9% of STAAR Surgical shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

STAAR Surgical presently has a consensus target price of $29.00, indicating a potential upside of 15.86%. CapsoVision has a consensus target price of $9.50, indicating a potential upside of 50.55%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts clearly believe CapsoVision is more favorable than STAAR Surgical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STAAR Surgical
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

CapsoVision has lower revenue, but higher earnings than STAAR Surgical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$239.44M5.25-$80.45MN/AN/A
CapsoVision$13.55M24.97-$25.32M-$0.45N/A

STAAR Surgical has a net margin of 0.16% compared to CapsoVision's net margin of -210.09%. STAAR Surgical's return on equity of 8.43% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
STAAR Surgical0.16% 8.43% 6.50%
CapsoVision -210.09%-160.23%-122.59%

STAAR Surgical has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, CapsoVision has a beta of -2.34, meaning that its stock price is 334% less volatile than the broader market.

In the previous week, CapsoVision had 2 more articles in the media than STAAR Surgical. MarketBeat recorded 5 mentions for CapsoVision and 3 mentions for STAAR Surgical. CapsoVision's average media sentiment score of 0.34 beat STAAR Surgical's score of 0.15 indicating that CapsoVision is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STAAR Surgical
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CapsoVision
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

STAAR Surgical beats CapsoVision on 8 of the 14 factors compared between the two stocks.

How does CapsoVision compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Tandem Diabetes Care presently has a consensus price target of $27.39, suggesting a potential upside of 63.06%. CapsoVision has a consensus price target of $9.50, suggesting a potential upside of 50.55%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, equities research analysts plainly believe Tandem Diabetes Care is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.58
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Tandem Diabetes Care had 17 more articles in the media than CapsoVision. MarketBeat recorded 22 mentions for Tandem Diabetes Care and 5 mentions for CapsoVision. Tandem Diabetes Care's average media sentiment score of 0.99 beat CapsoVision's score of 0.34 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
10 Very Positive mention(s)
7 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CapsoVision
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tandem Diabetes Care has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, CapsoVision has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market.

CapsoVision has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.16-$204.71M-$0.72N/A
CapsoVision$13.55M24.97-$25.32M-$0.45N/A

Tandem Diabetes Care has a net margin of -4.58% compared to CapsoVision's net margin of -210.09%. Tandem Diabetes Care's return on equity of -35.61% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-4.58% -35.61% -4.53%
CapsoVision -210.09%-160.23%-122.59%

Summary

Tandem Diabetes Care beats CapsoVision on 11 of the 14 factors compared between the two stocks.

How does CapsoVision compare to Artivion?

Artivion (NYSE:AORT) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Artivion currently has a consensus target price of $39.00, suggesting a potential upside of 110.19%. CapsoVision has a consensus target price of $9.50, suggesting a potential upside of 50.55%. Given Artivion's stronger consensus rating and higher possible upside, research analysts plainly believe Artivion is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artivion
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Artivion has a net margin of -3.65% compared to CapsoVision's net margin of -210.09%. Artivion's return on equity of 5.12% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
Artivion-3.65% 5.12% 2.36%
CapsoVision -210.09%-160.23%-122.59%

86.4% of Artivion shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 2.3% of CapsoVision shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, CapsoVision had 3 more articles in the media than Artivion. MarketBeat recorded 5 mentions for CapsoVision and 2 mentions for Artivion. CapsoVision's average media sentiment score of 0.34 beat Artivion's score of -0.55 indicating that CapsoVision is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Artivion
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
CapsoVision
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Artivion has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, CapsoVision has a beta of -2.34, meaning that its share price is 334% less volatile than the broader market.

Artivion has higher revenue and earnings than CapsoVision. Artivion is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artivion$441.33M2.05$9.77M-$0.36N/A
CapsoVision$13.55M24.97-$25.32M-$0.45N/A

Summary

Artivion beats CapsoVision on 12 of the 15 factors compared between the two stocks.

How does CapsoVision compare to Alphatec?

Alphatec (NASDAQ:ATEC) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

CapsoVision has lower revenue, but higher earnings than Alphatec. CapsoVision is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alphatec$764.16M1.40-$143.36M-$0.55N/A
CapsoVision$13.55M24.97-$25.32M-$0.45N/A

Alphatec has a net margin of -10.35% compared to CapsoVision's net margin of -210.09%. CapsoVision's return on equity of -160.23% beat Alphatec's return on equity.

Company Net Margins Return on Equity Return on Assets
Alphatec-10.35% -6,752.24% -9.77%
CapsoVision -210.09%-160.23%-122.59%

66.4% of Alphatec shares are held by institutional investors. 13.5% of Alphatec shares are held by company insiders. Comparatively, 2.3% of CapsoVision shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Alphatec had 16 more articles in the media than CapsoVision. MarketBeat recorded 21 mentions for Alphatec and 5 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.34 beat Alphatec's score of -0.51 indicating that CapsoVision is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alphatec
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Negative
CapsoVision
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alphatec has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, CapsoVision has a beta of -2.34, meaning that its stock price is 334% less volatile than the broader market.

Alphatec currently has a consensus price target of $15.37, suggesting a potential upside of 122.71%. CapsoVision has a consensus price target of $9.50, suggesting a potential upside of 50.55%. Given Alphatec's stronger consensus rating and higher probable upside, analysts clearly believe Alphatec is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alphatec
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Alphatec beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does CapsoVision compare to Alpha Tau Medical?

CapsoVision (NASDAQ:CV) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Alpha Tau Medical had 10 more articles in the media than CapsoVision. MarketBeat recorded 15 mentions for Alpha Tau Medical and 5 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.34 beat Alpha Tau Medical's score of 0.28 indicating that CapsoVision is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CapsoVision
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alpha Tau Medical
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CapsoVision has higher revenue and earnings than Alpha Tau Medical. CapsoVision is trading at a lower price-to-earnings ratio than Alpha Tau Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CapsoVision$13.55M24.97-$25.32M-$0.45N/A
Alpha Tau MedicalN/AN/A-$42.63M-$1.04N/A

CapsoVision has a beta of -2.34, meaning that its stock price is 334% less volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

2.7% of Alpha Tau Medical shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alpha Tau Medical has a net margin of 0.00% compared to CapsoVision's net margin of -210.09%. Alpha Tau Medical's return on equity of -138.12% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
CapsoVision-210.09% -160.23% -122.59%
Alpha Tau Medical N/A -138.12%-81.68%

CapsoVision presently has a consensus price target of $9.50, suggesting a potential upside of 50.55%. Alpha Tau Medical has a consensus price target of $18.20, suggesting a potential upside of 60.61%. Given Alpha Tau Medical's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Tau Medical is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Alpha Tau Medical
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Alpha Tau Medical beats CapsoVision on 10 of the 14 factors compared between the two stocks.

Get CapsoVision News Delivered to You Automatically

Sign up to receive the latest news and ratings for CV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CV vs. The Competition

MetricCapsoVisionHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$365.62M$5.92B$7.59B$11.70B
Dividend YieldN/A1.69%2.48%4.65%
P/E RatioN/A35.3931.9926.76
Price / Sales24.975.328.405.53
Price / CashN/A23.4220.7221.66
Price / Book12.884.154.423.65
Net Income-$25.32M$143.14M$3.51B$394.00M
7 Day Performance4.64%-4.63%-5.44%-5.74%
1 Month Performance-5.54%-6.63%-8.62%-9.54%
1 Year Performance18.39%-1.01%-1.31%-6.71%

CapsoVision Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CV
CapsoVision
3.5446 of 5 stars
$6.31
-7.5%
$9.50
+50.6%
+18.4%$365.62M$13.55MN/A99
STAA
STAAR Surgical
2.4239 of 5 stars
$24.55
-2.6%
$29.00
+18.1%
-5.4%$1.36B$239.44MN/A957
TNDM
Tandem Diabetes Care
2.9587 of 5 stars
$18.17
+7.5%
$27.18
+49.6%
-10.4%$1.33B$1.01BN/A2,500
AORT
Artivion
2.8424 of 5 stars
$20.72
+2.5%
$39.00
+88.3%
-58.5%$1.29B$441.33M48.981,800
ATEC
Alphatec
3.924 of 5 stars
$7.38
-0.8%
$15.63
+111.8%
-64.8%$1.28B$764.16MN/A913

Related Companies and Tools


This page (NASDAQ:CV) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners